> Back to EJC

2016 editions

  • December 2016
    Joao Incio on mechanisms to explain why obesity promotes cancer.
  • November 2016
    Mike Stratton on how mutational changes in a cancer genome can point to the cause of the cancer.
  • October 2016
    Ruth Muschel on a new target for treatments for colorectal cancer.
  • September 2016
    Freddie Hamdy on the effectiveness of treatments for prostate cancer.
  • August 2016
    Moshe Oren discusses the effects of the microenvironment on cancer cells.
  • July 2016
    Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer.
  • June 2016
    Key advances in clinical trials.
  • May 2016
    Mark Lemmon on the underlying biochemistry of cancer.
  • April 2016
    Roger Stupp on using alternating electric fields as treatment.
  • March 2016
    Charlotte Vrinten on public perception of deaths from cancer.
  • February 2016
    Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
  • December 2015/January 2016
    Nazneen Rahman on germline genetic screening in ovarian cancer.

> All 2015 Editions

> All 2014 Editions

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

EJC News Focus – November/December 2012

Loading EJC News Focus video

Take-home messages from ESMO 2012

Whether it’s the unforeseen and positive consequences of combining two drugs in melanoma, the first head-to-head trial of pazopanib in kidney cancer, or a Spanish presentation on lung cancer which will send researchers back to the drawing board, the messages from ESMO 2012 were many and varied. The importance of understanding cancer biology before progressing in trials was discussed, along with the affordability, or lack of it, of current approaches.

Here, Reinhard Dummer, Manuela Schmidinger, Riitta Kokko, Solange Peters, Jean-Yves Blay and Richard Sullivan tell Helen Saul what they found to be the most important take-home messages.